ストックスクリーナーアプリを入手
1.60
8.57%
-0.15
アフターアワーズ：
1.62
0.02
+1.25%
前日終値:
$1.75
開ける：
$1.71
24時間の取引高:
928.35K
Relative Volume:
1.08
時価総額：
$115.36M
収益：
$20.76M
当期純損益:
$-132.49M
株価収益率:
-0.5993
EPS:
-2.67
ネットキャッシュフロー:
$-108.55M
1週間 パフォーマンス:
-27.93%
1か月 パフォーマンス:
-40.96%
6か月 パフォーマンス:
-71.93%
1年 パフォーマンス:
-80.42%
1日の値動き範囲:
$1.585
$1.73
1週間の範囲:
$1.585
$2.23
52週間の値動き範囲:
$1.585
$8.29
C 4 Therapeutics Inc Stock (CCCC) Company Profile
CCCC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CCCC
C 4 Therapeutics Inc
|
1.60 | 115.36M | 20.76M | -132.49M | -108.55M | -2.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-19 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | 開始されました | Stephens | Equal-Weight |
| 2024-01-29 | アップグレード | JP Morgan | Underweight → Neutral |
| 2023-12-13 | アップグレード | Stifel | Hold → Buy |
| 2023-02-24 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2023-02-24 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2022-11-04 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-10-11 | 開始されました | Morgan Stanley | Underweight |
| 2022-04-28 | 開始されました | Credit Suisse | Underperform |
| 2022-04-11 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-03-10 | 開始されました | JP Morgan | Overweight |
| 2022-02-11 | 再開されました | BMO Capital Markets | Outperform |
| 2022-02-10 | 開始されました | Wells Fargo | Equal Weight |
| 2021-11-23 | 開始されました | BofA Securities | Buy |
| 2021-10-14 | 開始されました | SVB Leerink | Mkt Perform |
| 2021-09-30 | 開始されました | Stifel | Hold |
| 2021-06-04 | 開始されました | H.C. Wainwright | Buy |
| 2021-03-31 | 開始されました | BMO Capital Markets | Outperform |
| 2020-10-28 | 開始されました | UBS | Buy |
| 2020-10-27 | 開始されました | BMO Capital Markets | Outperform |
| 2020-10-27 | 開始されました | Jefferies | Buy |
すべてを表示
C 4 Therapeutics Inc (CCCC) 最新ニュース
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
C4 Therapeutics stock plunges to 52-week low of $1.95 By Investing.com - Investing.com South Africa
C4 Therapeutics stock plunges to 52-week low of $1.95 - Investing.com
Summit Therapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4) - Marketscreener.com
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Dyne Therapeutics Reports Inducement Grants Under Nasdaq - GlobeNewswire
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer - Yahoo Finance
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - TradingView
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
C4 Therapeutics: Getting Too Cheap To Ignore, But There's Still A Lot Of Risk Here - Seeking Alpha
Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
C4 Therapeutics stock hits 52-week low at $2.21 - Investing.com India
C4 Therapeutics stock hits 52-week low at $2.21 By Investing.com - Investing.com UK
Rhumbline Advisers Has $360,000 Stock Position in C4 Therapeutics, Inc. (NASDAQ:CCCC) - Defense World
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Y Intercept Hong Kong Ltd Invests $83,000 in C4 Therapeutics, Inc. (NASDAQ:CCCC) - Defense World
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
C4 Therapeutics, Inc. (NASDAQ:CCCC) Looks Inexpensive After Falling 31% But Perhaps Not Attractive Enough - Simply Wall St
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Marketscreener.com
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Intellia Therapeutics Expands Team: What the New Employee Stock Grants Mean for Investors - Stock Titan
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Marketscreener.com
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Marketscreener.com
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
C4 Therapeutics (CCCC) Loses -21.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Marketscreener.com
UBS Adjusts C4 Therapeutics Price Target to $3.50 From $4, Maintains Neutral Rating - Marketscreener.com
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Lags Revenue Estimates - MSN
C4 Therapeutics (CCCC) Loses -23.14% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
C4 Therapeutics (NASDAQ:CCCC) Posts Quarterly Earnings Results, Misses Expectations By $0.05 EPS - MarketBeat
C 4 Therapeutics Inc (CCCC) 財務データ
収益
当期純利益
現金流量
EPS
1.05%
1.79%
大文字化:
|
ボリューム (24 時間):